Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Genomics Inks MDx Development Deal with Moffitt Cancer Center

NEW YORK (GenomeWeb) – Rosetta Genomics announced today that it will collaborate with the Moffitt Cancer Center on the development of a microRNA-based diagnostic for thyroid neoplasia.

According to Rosetta, between four and seven percent of the general population develops thyroid nodules, but fewer than 10 percent of these are malignant. Fine needle aspiration (FNA) is routinely conducted to obtain tissue for biopsy, but analyses of these samples are often inconclusive.

Rosetta has been developing an assay that extracts miRNAs from FNA samples and uses their expression levels to differentiate malignant nodules from benign ones.

To assist in this effort, Rosetta said it will work with Moffitt researcher Marino Leon to help it further advance the development of the assay, with the goal of launching the test before the end of 2015.

Financial and other terms of the agreement were not disclosed.